How Effective Is Stelara for Psoriasis?
Stelara (ustekinumab) treats moderate to severe plaque psoriasis in adults and children 6 years and older by blocking IL-12 and IL-23, cytokines that drive inflammation.[1] In pivotal trials like Phoenix 1 and 2, 67-76% of patients achieved PASI 75 (75% skin clearance) at week 12 after two doses, compared to 4% on placebo. PASI 90 (90% clearance) reached 36-51%, and PASI 100 (complete clearance) hit 13-21%.[2][3]
Long-term data shows sustained response: over 80% maintained PASI 75 at week 28 with every-12-week dosing, and many kept near-complete clearance for years with retreatment as needed.[4]
Who Responds Best to Stelara?
Patients with higher baseline severity often see bigger improvements—those with PASI >20 had up to 80% PASI 75 rates. Responders typically weigh under 100kg for optimal subcutaneous dosing. About 5-10% are primary non-responders, often due to prior biologic failures.[2][5] Real-world studies confirm 60-70% PASI 75 at 6 months, slightly lower than trials due to comorbidities like obesity.[6]
How Does Stelara Compare to Other Biologics?
| Biologic | PASI 75 at Week 12 | PASI 90 at Week 12 | Dosing Frequency |
|----------|---------------------|---------------------|------------------|
| Stelara | 67-76% | 36-51% | Every 12 weeks |
| Humira (adalimumab) | 71-80% | 40-50% | Every 2 weeks |
| Cosentyx (secukinumab) | 80-85% | 55-65% | Every 4 weeks |
| Skyrizi (risankizumab) | 85-90% | 70-75% | Every 12 weeks |
Stelara matches older TNF inhibitors but trails IL-17/IL-23 rivals in speed and depth of response. It excels in convenience with fewer injections.[3][7] Head-to-head trials like Clear show secukinumab slightly edges it (86% vs 67% PASI 90).[8]
When Do Patients See Results and How Long Do They Last?
Improvement starts by week 4 (20-30% PASI reduction), peaks at week 12. Most maintain benefits 3-5 years with dosing every 12 weeks; 70-80% avoid retreatment.[4] Loss of response occurs in 10-20% over time, often from anti-drug antibodies (neutralized by monitoring).[5]
What Do Patient Reviews and Real-World Data Say?
On platforms like Drugs.com, Stelara scores 7.5/10 from psoriasis users, with 65% reporting major clearance but complaints about injection pain and cost. Real-world registries (e.g., British BADBIR) show 65% achieve clear/almost clear skin at 1 year, better than methotrexate (40%) but similar to other biologics.[6][9]
Common Concerns: Side Effects and Limitations
Infections (upper respiratory, 10-15%) and serious events (1-2%, like cellulitis) occur, but malignancy risk matches placebo over 5 years. Not ideal for pustular or erythrodermic psoriasis subtypes.[2][4] Pregnancy data is limited; use weighs risks.
[1]: FDA Stelara Label
[2]: Papp et al., Lancet 2008 (Phoenix 1)
[3]: Griffiths et al., NEJM 2010 (Phoenix 2)
[4]: Blauvelt et al., J Am Acad Dermatol 2017 (5-year)
[5]: Menter et al., J Drugs Dermatol 2014
[6]: BADBIR Registry, Br J Dermatol 2020
[7]: McInnes et al., Lancet 2017 (Cosentyx head-to-head)
[8]: Thaci et al., Clear trial, NEJM 2015
[9]: Drugs.com User Reviews